We are heading to the 16TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD)

BOSTON, MA (USA) on 24-27 October 2023. Our CEO, Chere Chapman, will present a poster showcasing our latest collaboration with INmune Bio showcasing methods for standardizing the implementation of #GoalAttainmentScaling in a Phase 2 study of pegipanermin (XPro1595) in patients with early Alzheimer’s disease and biomarkers of inflammation.

If you would like to meet with us at the conference, please contact us to schedule a meeting.